10q10k10q10k.net
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.CGEMEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted oncology therapies to address unmet medical needs for patients with hard-to-treat cancers. Its core pipeline includes candidates for solid tumors and hematological malignancies, with operations and R&D partnerships spanning North America and global oncology research networks.

Q4 2022Q3 2022Q2 2022Q1 2022

CGEM Q4 FY2022 Key Financial Metrics

Revenue

$0

Gross Profit

N/A

Operating Profit

$-32.6M

Net Profit

$-26.8M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.58

Cullinan Therapeutics, Inc. Q4 FY2022 Financial Summary

Cullinan Therapeutics, Inc. reported revenue of $0 for Q4 FY2022, with a net profit of $-26.8M (up 17.6% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net Profit$-26.8M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ4 FY2022

Cullinan Therapeutics, Inc. Annual Revenue by Year

Cullinan Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $0).

YearAnnual Revenue
2022$0—

Cullinan Therapeutics, Inc. Quarterly Revenue & Net Profit History

Cullinan Therapeutics, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2022$0—$-26.8MN/A
Q3 FY2022$0—$-24.8MN/A
Q2 FY2022$0—$174.9MN/A
Q1 FY2022$0—$-12.1MN/A

Income Statement

Q1 2022Q2 2022Q3 2022Q4 2022
Revenue$0$0$0$0
YoY GrowthN/AN/AN/AN/A

Balance Sheet

Q1 2022Q2 2022Q3 2022Q4 2022
Assets$437.5M$667.2M$617.2M$561.1M
Liabilities$18.0M$62.6M$31.1M$26.1M
Equity$418.7M$604.5M$586.1M$535.0M

Cash Flow

Q1 2022Q2 2022Q3 2022Q4 2022
Operating CF$-21.9M$-25.4M$-54.4M$-25.0M